DURECT Co. (NASDAQ:DRRX) Short Interest Update

DURECT Co. (NASDAQ:DRRX) saw a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 809,100 shares, a decline of 6.9% from the January 15th total of 868,800 shares. Currently, 2.9% of the company’s stock are short sold. Based on an average daily volume of 103,200 shares, the days-to-cover ratio is currently 7.8 days.

Analyst Ratings Changes

Several research firms have recently commented on DRRX. StockNews.com began coverage on shares of DURECT in a report on Saturday. They set a “sell” rating on the stock. HC Wainwright reiterated a “neutral” rating on shares of DURECT in a report on Thursday, November 14th.

Institutional Trading of DURECT

Several institutional investors have recently made changes to their positions in DRRX. Jane Street Group LLC lifted its holdings in DURECT by 266.0% during the 4th quarter. Jane Street Group LLC now owns 39,196 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 28,486 shares during the last quarter. Geode Capital Management LLC lifted its holdings in DURECT by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock valued at $429,000 after purchasing an additional 14,658 shares during the last quarter. Finally, Richmond Brothers Inc. lifted its holdings in DURECT by 12.2% during the 4th quarter. Richmond Brothers Inc. now owns 1,281,176 shares of the specialty pharmaceutical company’s stock valued at $961,000 after purchasing an additional 138,920 shares during the last quarter. 28.03% of the stock is currently owned by institutional investors and hedge funds.

DURECT Stock Performance

Shares of DURECT stock remained flat at $0.77 during midday trading on Tuesday. 28,891 shares of the stock traded hands, compared to its average volume of 65,848. The company’s fifty day moving average price is $0.83 and its 200 day moving average price is $1.12. The company has a market cap of $23.87 million, a PE ratio of -1.26 and a beta of 0.91. DURECT has a twelve month low of $0.70 and a twelve month high of $1.88.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.